Drug · Monoclonal Antibody

Ramucirumab

CI-DRUG-00000507Explore in graph →NCIt C70792 CHEMBL1743062 CIViC Approved

Regulatory

Approvals (14)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory14 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as CYRAMZA (DIN 02443805) under ATC L01FG02 RAMUCIRUMAB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Sep 10, 2015	health-canada-dpd
EU EMA	—	Gastric cancer Cyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy. Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate. Colorectal cancer Cyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5?fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. Non-small cell lung cancer Cyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy. Hepatocellular carcinoma Cyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ? 400 ng/ml and who have been previously treated with sorafenib.	approved	Dec 19, 2014	ema

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 3	37	16	21	135	14	CA, EU, US	Apr 21, 2014	2005-01
Malignant Lung Neoplasm	Approved	Phase 3	18	7	6	37	2	US	Apr 21, 2014	2009-01
Malignant Liver Neoplasm	Approved	Phase 3	0	0	1	7	1	US	Apr 21, 2014	2008-02
Malignant Gastric Neoplasm	Phase3	Phase 3	13	6	8	37	0

Curated evidence

Clinical evidence (3)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ERBB2 R678Q1
Ramucirumab	Gastric Adenocarcinoma

Clinical trials

Trials with this intervention (137)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 137 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06203600	Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial	recruiting	Phase 2 / Phase 3	224	National Cancer Institute (NCI)NIH	1	Sep 25, 2026	clinicaltrials
NCT04340882	Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade(DoceRamPem)

Molecule

Record

Kind: Monoclonal Antibody
Mechanism: Vascular endothelial growth factor receptor 2 inhibitor
Targets: 1 gene
UNII: D99YVK4L0X
Aliases: 1121B, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, CYRAMZA, IMC 1121B, IMC-1121B, IMC1121B, LY 3009806, LY3009806, Monoclonal Antibody HGS-ETR2, Ramucirumab

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (5)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01FG02	RAMUCIRUMAB
ATC (WHO)	L01FX06	Antineoplastic agents
DIN (Health Canada)